Claas Wesseler
A5088353125- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Pleural and Pulmonary Diseases
- PI3K/AKT/mTOR signaling in cancer
- Chronic Lymphocytic Leukemia Research
- COVID-19 and healthcare impacts
- Neuroendocrine Tumor Research Advances
- Gastric Cancer Management and Outcomes
- Advanced Breast Cancer Therapies
- Cancer therapeutics and mechanisms
- Long-Term Effects of COVID-19
- HER2/EGFR in Cancer Research
- Radiomics and Machine Learning in Medical Imaging
- COVID-19 Clinical Research Studies
- Occupational and environmental lung diseases
- Peptidase Inhibition and Analysis
- Economic and Financial Impacts of Cancer
- Medical Imaging and Pathology Studies
- Neuroblastoma Research and Treatments
- Cancer Research and Treatments
- Medical Practices and Rehabilitation
Asklepios Klinikum Harburg
2017-2025
Mammazentrum Hamburg
2023
Asklepios
2023
PURPOSE Epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for -mutant, metastatic non–small cell lung cancer (NSCLC); however, most patients experience disease progression. We report results from the randomized, double-blind, phase III KEYNOTE-789 study of pemetrexed and platinum–based chemotherapy with or without pembrolizumab TKI-resistant, nonsquamous NSCLC (ClinicalTrials.gov identifier: NCT03515837 ). METHODS Adults...
The open-label, phase III EVOKE-01 study evaluated sacituzumab govitecan (SG) versus standard-of-care docetaxel in metastatic non-small cell lung cancer (mNSCLC) with progression on/after platinum-based chemotherapy, anti-PD-(L)1, and targeted treatment for actionable genomic alterations (AGAs). Primary analysis is reported.
Neuregulin 1 (NRG1) fusions are oncogenic drivers that have been detected in non-small-cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC) and other solid tumors. NRG1 rare, occurring less than 1% of Patients with fusion positive (NRG1+) limited therapeutic options. Zenocutuzumab is a novel, bispecific IgG1 antibody targets both HER2 HER3 proteins inhibits binding through 'Dock & Block®' mechanism action. Here, we describe the rationale design phase II component eNRGy trial,...
Programmed death-ligand 1 expression currently represents the only validated predictive biomarker for immune checkpoint inhibition in metastatic NSCLC clinical routine, but it has limited value distinguishing responses. Assessment of KRAS and TP53 mutations (mut) as surrogate an immunosupportive tumor microenvironment (TME) might help to close this gap.
The immune surveillance reactivator lefitolimod (MGN1703), a DNA-based TLR9 agonist, might foster innate and adaptive response thus improve immune-mediated control of residual cancer disease. IMPULSE phase II study evaluated the efficacy safety as maintenance treatment in extensive-stage small-cell lung (ES-SCLC) after objective to first-line chemotherapy, an indication with high unmet medical need stagnant improvement last decades.103 patients ES-SCLC tumor (as per RECIST 1.1) following...
JUNIPER compared the efficacy and safety of abemaciclib, a selective cyclin-dependent kinase 4 6 inhibitor, with erlotinib in patients non-small cell lung cancer (NSCLC) harboring Kirsten rat sarcoma (KRAS) mutation. was Phase III, multicenter, randomized, open-label trial abemaciclib versus stage IV NSCLC detectable mutation codons 12 or 13 KRAS oncogene, who progressed after platinum-based chemotherapy 1 additional therapy (could include immune checkpoint inhibitor therapy). Randomized...
EGFR exon 20 (EGFR Ex20) insertion mutations in non-small cell lung cancer (NSCLC) are insensitive to traditional tyrosine kinase inhibitors (TKIs). Mobocertinib is the only approved TKI specifically designed target Ex20. We performed an international, real-world safety and efficacy analysis on patients with Ex20-positive NSCLC enrolled a mobocertinib early access program. explored mechanisms of resistance by analyzing postprogression biopsies, as well cross-resistance amivantamab. Data from...
Chemotherapy plus immune-checkpoint inhibitor (CTx+ICI) therapy has become the preferred 1st line treatment in patients with metastatic NSCLC without oncogenic driven mutations. However, optimal subsequent 2nd is not defined and several alternatives exist. The purpose of this analysis was to evaluate efficacy docetaxel ramucirumab (D+R) initiated after failure CTx+ICI.Retrospective data were collected during routine care from German thoracic oncology centers. Only who had received at least...
Background: Antiangiogenic agents have been shown to stimulate the immune system and cause synergistic effects with chemotherapy. Effects might be even stronger after immune-checkpoint-inhibitor (ICI) therapy. The purpose of this analysis was evaluate efficacy ramucirumab plus docetaxel (R + D) as third-line treatment failure a first-line platinum-based chemotherapy second-line ICI in patients non-small-cell lung cancer (NSCLC) stage IV. Methods: Retrospective data were collected from 9...
Ziel/Aim: Optimal duration of immune checkpoint blocker (ICB)-treatment in lung cancer has not been determined yet. One five patients treated with first-line ICB achieves durable responses for≥2 years. Treatment continuation beyond 2 years impacts on economic burden and might cause avoidable toxicities. Thus, safe discontinuation strategies represent an urgent medical need.
9025 Background: Approximately 30% of NSCLC tumors harbor KRAS mutations, for which there is no specific treatment. Abemaciclib a potent and selective inhibitor CDK4 & 6 approved treatment HR+, HER2- advanced breast cancer. In Phase 1 study, abemaciclib showed greater clinical activity in patients with mutant versus wild type tumors. This study compared erlotinib, both best supportive care, previously treated mutations. Methods: was global, 3, comparator-controlled, multicenter, open-label...
Background After one year of the pandemic and hints seasonal patterns, temporal variations in-hospital mortality in COVID-19 are widely unknown. Additionally, heterogeneous data regarding clinical indicators predicting disease severity has been published. However, there is a need for risk stratification model integrating effects on to support decision-making. Methods We conducted multicenter, observational, prospective, epidemiological cohort study at 45 hospitals Germany. Until 1 January...
Dementia has been identified as a major predictor of mortality associated with COVID-19.The objective this study was to investigate the association between dementia and in COVID-19 inpatients Germany across longer interval during pandemic.This retrospective based on anonymized data from 50 hospitals included patients confirmed diagnosis hospitalized March 11, 2020 July, 20, 2022. The main outcome inpatient stays diagnosis, which studied using multivariable logistic regression adjusted for...
In recent years, Non-small cell lung cancer (NSCLC) has evolved into a prime example for precision oncology with multiple FDA-approved “precision” drugs. For the majority of NSCLC lacking targetable genetic alterations, immune checkpoint inhibition (ICI) become standard care in first-line treatment or beyond. PD-L1 tumor expression represents only approved predictive biomarker PD-L1/PD-1 by therapeutic antibodies. Since PD-L1-negative low-expressing tumors may also respond to ICI, additional...
Highlights•Small cell transformation occurs about 1.5 years after start of targeted therapy•Immunotherapy was associated with a non-significant trend towards longer survival•Efficacy treatment lines platinum/etoposide is limited•The majority tumors acquires DLL3 expression small transformationAbstractIntroductionSmall (SCT) typical mechanism adaptive resistance to third generation epidermal growth factor receptor inhibitors (EGFRi) which have become the standard care for EGFR-driven...
e21220 Background: Recently FLAURA study demonstrated significant PFS and numeric OS benefit for Osimertinib 1st line vs. gen. TKI's. The number of pts switching from to 3rd TKI (30%) appeared be low it is questionable whether these data represent real world sequencing treatment patterns. Therefore, we investigated the sequence pattern, i.e. percentage 2nd therapy in EGFR mt+ 3 lung cancer centers Germany. Methods: Data 912/1477 tested were analyzed between 2009-2017. 140/144 patients with...
Background: Acute myocardial injury (AMJ), assessed by elevated levels of cardiac troponin, is associated with fatal outcome in coronavirus disease 2019 (COVID-19). However, the role acute cardiovascular (CV) events defined clinical manifestation rather than sole elevations biomarkers unclear hospitalized COVID-19 patients. Objective: The aim this study was to investigate clinically manifest CV Methods: From 1 March 2020 5 January 2021, we conducted a multicenter, prospective,...
Introduction: SARS-CoV-2 infected patients with cancer have a worse outcome including significant higher mortality, compared to non-cancer patients. However, limited data are available regarding in-hospital mortality during the Omicron phase of pandemic. Therefore, aim study was comparison in history and active disease different phases COVID-19 pandemic, focusing on current variant concern. Methods: We conducted multicenter, observational, epidemiological cohort at 45 hospitals Germany....
Introduction:Patients with metastatic non-small-cell lung cancer (mNSCLC) treated immune checkpoint inhibitors (CPIs) in clinical practice may often not meet the strict inclusion criteria of trials.Our aim was to assess trial eligibility patients mNSCLC pembrolizumab monotherapy real-world and compare outcome "trialineligible" "potentially trial-eligible" patients.Methods: Data from prospective, research platform CRISP were used patient characteristics, treatment programmed cell death-ligand...